AbstRACt: Aromatic L-amino acid decarboxylase (AADC) deficiency (MIM #608643) is an autosomal recessive inborn error of monoamines. It is caused by a mutation in the DDC gene that leads to a deficiency in the AADC enzyme. The clinical features of this condition include a combination of dopamine, noradrenaline, and serotonin deficiencies, and a patient may present with hypotonia, oculogyric crises, sweating, hypersalivation, autonomic dysfunction, and progressive encephalopathy with severe developmental delay. We report the case of an 8-month-old boy who presented with the abovementioned symptoms and who was diagnosed with AADC deficiency based on clinical, biochemical, and molecular investigations. Treatment with bromocriptine and pyridoxine showed no improvement. These data support the findings observed among previously reported cohorts that showed poor response of this disease to current regimens. Alternative therapies are needed to ameliorate the clinical complications associated with this disorder.
Introduction
Aromatic L-amino acid decarboxylase (AADC) deficiency (Online Mendelian Inheritance in Man (OMIM ® #608643) is an autosomal recessive neurotransmitter disorder. [1] [2] [3] It is caused by a deficiency in AADC due to a mutation in the AADC gene (DDC) on chromosome 12p12.3-p12. 3, 4 This leads to deficiencies in combined monoamines, catecholamines, and serotonin. It is characterized clinically by global developmental delay, truncal hypotonia, oculogyric crises, dystonia, sweating, severe progressive epileptic encephalopathy, and other signs of catecholamine and serotonin deficiencies. [2] [3] [4] [5] Diagnosis relies on the presence of a characteristic cerebrospinal fluid (CSF) profile (low homovanillic acid, 5-hydroxyindoleacidicacid, and 3-methoxy-4-hydroxyphenolglycole, as well as elevated 3-O-methyl-L-dopa, L-dopa, and 5-hydroxytryptophan), the absence of plasma AADC activity, or elevated urinary vanillactic acid, and confirmation of the sequencing of the DOPA decarboxylase (DDC) gene. 2, 3, 6 To date, there is no cure for AADC deficiency, and there are conflicting data in the literature regarding the best treatment options. 7 However, the first-line medications appear to be dopamine agonists, such as bromocriptine combined with pyridoxine. 3, 4 We report the case of an 8-month-old boy diagnosed with an AADC deficiency who did not respond to bromocriptine and pyridoxine treatment. parameters and did not have a significant antenatal history. He was discharged at the second day of life with no complications. The child presented to King Abdulaziz Medical City at 4.5 months of age when he developed a fever and flu-like symptoms, requiring admission to the Pediatric Intensive care Unit for 5 days. On reviewing his clinical history, the parents noticed that he was floppy a few days after birth. In addition, they noticed abnormal posturing of his right lower limbs with eye conversion that last for few minutes, but which recurred frequently at 2 months of age. Furthermore, he demonstrated excessive sweating and difficulties with feeding. His developmental history showed a global developmental delay with poor head control; there was no cooing, no social smile, he did not roll over, and he did not sit. His developmental age was equal to 1 month.
On examination, the growth parameters showed the following: length, 82 cm (50th percentile); weight, 11.07 kg (2nd percentile); and head circumference, 47 cm (50th percentile) with no dysmorphic features or neurocutaneous stigmata. Neurological examination showed: bilateral positive red reflex; not fixing or following; axial hypotonia with peripheral hypertonia; dystonic posture; and hyperreflexia of all limbs. Other systemic examinations demonstrated no significant abnormalities.
Additional diagnostic investigations were unrevealing. Continuous electroencephalogram (EEG) monitoring for 2 days was normal, and it was concluded that these attacks were consistent with occulogyris crises. An echocardiogram was normal. Brain computed tomography (CT) was normal. Brain and spine magnetic resonance imaging (MRI) showed no intracranial abnormality. Auditory brainstem response showed a central defect in the right auditory pathway. The ophthalmologic evaluation was normal.
All the following investigations were also unremarkable: complete blood count, liver enzymes, serum electrolytes and renal function. Biochemical investigations included acylcarnitine profile, plasma aminoacids were unremarkable. Urine organic acids showed moderately elevated homovanillic acid and slight elevation of methylglutaric and methylglutaconic acids.
A neurotransmitter metabolite cerebrospinal fluid (CSF) panel showed reduced concentrations of homovanillic acid 60 nmol/L (403-919 nmol/L) and 5-OH-indolacetic acid 93 nmol/L (170-412 nmol/L), as well as their ratio of 0.6 (1.8-3), and a clearly increased concentration of 3-ortho methyl dopa of 2,076 nmol/L (0-50 nmol/L). The plasma levels of amine neurotransmitter metabolites showed the following: vanillymandelicacid (3.9; 12-73 nmol/L), 3-methoxy-4-hydroxy-phenylglycol (2.4; 9-37 nmol/L) and homovanillic acid (19.3; 43-131 nmol/L) were strongly decreased; while 5-hydroxyindolacetic acid was borderline low (33.1; 21-183 nmol/L). Vanillactic acid (478 nmol/L), which is the metabolite of a dopamine precursor, was strongly increased; this metabolite pattern is fully characteristic of an AADC deficiency. The plasma AADC enzyme activity was 4 pmol/ mlMin (47-119 pmol/mlMin) which is clearly reduced. Sequence analysis of the DDC gene identified a homozygous missense mutation c.1234C.T (p. R412W). The parents were tested and found to be carriers for this mutation. After the diagnosis was confirmed, the patient was started on pyridoxine at 100 mg orally, every 12 (q12) hours, and bromocriptine at 10 mg orally q12 hours. However, the proband continued to present with agitation and insomnia with no improvement in the duration or frequency of the occulogyris crises. Two months later, the medications were stopped, as the patient did not appear to respond to treatment. discussion AADC deficiency was first described by Hyland and Clayton in 1990, when they reported on male monozygotic twins who presented at the age of 2 months with severe hypotonia and oculogyric crises. 8 Subsequently, AADC deficiency has been reported in almost 80 patients worldwide. 1, 3, 4 The most consistent features associated with this deficiency are those of combined dopamine and noradrenaline deficiency. The signs of dopamine deficiency include hypokinesia, rigidity, dystonia (with or without diurnal variations), distal chorea, and oculogyric crises. The clinical features of noradrenaline insufficiency include ptosis, miosis, profuse oropharyngeal secretions, postural hypotension, autonomic dysfunction, and temperature instability. Similarly, symptoms of serotonin deficiency include sleep disorders, memory and learning disabilities, and behavioral disturbances. 9 Hypotonia and oculogyric crises are the most common clinical signs noted across all reported patients. 3 The patient presented in this report showed a mixture of these clinical features.
Treatment of AADC deficiency is supportive. The most common first-line treatments are bromocriptine and pyridoxine with dosages ranging between 40 mg/day and 1,800 mg/day (4.0-81 mg/kg/day) and 1.0-45.5 mg/day (0.013-4.0 mg/kg/day), respectively. Bromocriptine is a dopamine receptor agonist with high affinity for D2-like receptors, 4, 10 and has been prescribed to correct motor deficit like hypokinesia, axial hypotonia, limb hypertonia, dystonia and choreoathetosis. However, its effect has varied anmong individuals. 4 Pyridoxine or vitamin B 6 is also given to patients to boost residual AADC activity with a cofactor excess. 10 Other medications used in the management of affected children are monoamine oxidase inhibitors such as selegiline, pergolide, tranylcypromine, trihexyphenidyl, L-dopa, and folinic acid. 3, 4 Most of the reported patients, as well as current case, showed no response to these therapies (Table 1) . However, Brun et al. 3 (2010) presented 15 patients who improved on a combined therapy with pyridoxine, dopamine agonists, and monoamine oxidase B inhibitors.
Gene therapy is a promising experimental approach to AADC deficiency treatment of AADC deficiency, where the DCC gene may be transferred directly into patients' cells to stabilize the expression of the AADC protein. 10 The feasibility of gene therapy for AADC deficiency is underscored by a recent report of functional motor improvement in four children with AADC deficiency. Here, Hwu et al. applied the adeno-associated virus type 2 vector to deliver the DCC gene to the putamen area, without complications.
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Conclusion
We alert clinicians to consider AADC deficiency in any infant with hypotonia and oculogyric crises. We note that despite the poor clinical response to current medications, gene therapy shows promise as a treatment for this disorder.
